The relation between smokeless tobacco and cancer in Northern Europe and North America. A commentary on differences between the conclusions reached by two recent reviews by Lee, Peter N & Hamling, Jan
BioMed  Central
Page 1 of 10
(page number not for citation purposes)
BMC Cancer
Open Access Correspondence
The relation between smokeless tobacco and cancer in Northern 
Europe and North America. A commentary on differences between 
the conclusions reached by two recent reviews
Peter N Lee* and Jan Hamling
Address: P.N. Lee Statistics and Computing Ltd, Surrey, UK
Email: Peter N Lee* - PeterLee@pnlee.co.uk; Jan Hamling - JanHamling@pnlee.co.uk
* Corresponding author    
Abstract
Background: Smokeless tobacco is an alternative for smokers who want to quit but require
nicotine. Reliable evidence on its effects is needed. Boffetta et al. and ourselves recently reviewed
the evidence on cancer, based on Scandinavian and US studies. Boffetta et al. claimed a significant
60–80% increase for oropharyngeal, oesophageal and pancreatic cancer, and a non-significant 20%
increase for lung cancer, data for other cancers being "too sparse". We found increases less than
15% for oesophageal, pancreatic and lung cancer, and a significant 36% increase for oropharyngeal
cancer, which disappeared in recent studies. We found no association with stomach, bladder and
all cancers combined, using data as extensive as that for oesophageal, pancreatic and lung cancer.
We explain these differences.
Methods: For those cancers Boffetta et al. considered, we compared the methods, studies and
risk estimates used in the two reviews.
Results: One major reason for the difference is our more consistent approach in choosing
between study-specific never smoker and combined smoker/non-smoker estimates. Another is our
use of derived as well as published estimates. We included more studies, and avoided estimates for
data subsets. Boffetta et al. also included some clearly biased or not smoking-adjusted estimates.
For pancreatic cancer, their review included significantly increased never smoker estimates in one
study and combined smoker/non-smoker estimates in another, omitting a combined estimate in the
first study and a never smoker estimate in the second showing no increase. For oesophageal cancer,
never smoker results from one study showing a marked increase for squamous cell carcinoma were
included, but corresponding results for adenocarcinoma and combined smoker/non-smoker results
for both cell types showing no increase were excluded. For oropharyngeal cancer, Boffetta et al.
included a markedly elevated estimate that was not smoking-adjusted, and overlooked the lack of
association in recent studies.
Conclusion: When conducting meta-analyses, all relevant data should be used, with clear rules
governing the choice between alternative estimates. A systematic meta-analysis using pre-defined
procedures and all relevant data gives a lower estimate of cancer risk from smokeless tobacco
(probably 1–2% of that from smoking) than does the previous review by Boffetta et al.
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Background
In 2008, Boffetta et al. [1] published a short review in Lan-
cet Oncology of the evidence relating smokeless tobacco
(ST) to cancer. Included was a table summarizing smok-
ing-adjusted relative risk (RR) estimates with 95% confi-
dence intervals (CI) relating to cancer of the oral cavity,
oesophagus, pancreas and lung in the USA and Northern
Europe taken from 18 studies, together with a further
table of meta-analysis results. The results of the overall
(USA and Nordic countries combined) meta-analyses are
summarized in Table 1, and show a statistically significant
increase of 60–80% for ever smokeless tobacco use for
oral, oesophageal and pancreatic cancer, and a non-signif-
icant 20% increase for lung cancer. Results for other can-
cers were stated to be "too sparse for a quantitative
investigation."
In their review Boffetta et al. [1] give only limited informa-
tion on their "search strategy and selection criteria." While
they make it clear that they restricted attention to papers
published up to September 2007 (including one in press
at that time) they give little information on how they
selected the cancers for detailed study or how they chose
the estimates to be included in their meta-analyses. Thus
they note that results for cancers other than those of the
oral cavity, oesophagus, pancreas, and lung were "too
sparse for quantitative information" without specifying
the amount of data needed for analysis. Furthermore they
state merely that "we included only studies restricted to
non-smokers and studies that included smokers but were
properly adjusted for the possible confounding effect of
tobacco smoking." without giving any indication as to
how they chose from alternative estimates available in a
number of the papers (e.g. by sub-type of cancer, type of
smoking adjustment, type of ST or timing of ST exposure).
A meticulous description of the methods used should
have been included, but was not.
Shortly before the review of Boffetta et al. [1] was pub-
lished, we had started our own review of this evidence, a
review which has recently been published in BMC Medi-
cine [2]. We continued with our review, because our ini-
tial impression of Boffetta et al.'s was that some relevant
data had been missed and that some of the RRs used in
their meta-analyses seemed inappropriate. Although our
review also considered effect estimates that were not
adjusted for smoking, we took particular care to distin-
guish those that were adjusted for smoking. Our smoking-
adjusted meta-analysis estimates are also shown in Table
1. As will be seen, our estimates are substantially lower for
all four cancers considered by Boffetta et al. For oesopha-
geal, pancreatic and lung cancer the estimated increases
are all less than 15% and not statistically significant, while
for oral cancer our estimate of a 36% increase, though sta-
tistically significant, is lower than the 80% increase esti-
mated by Boffetta et al., and disappears when attention is
restricted to studies published since 1990. Our review also
considers a range of other cancers, and Table 1 also
presents meta-analysis estimates for stomach, bladder and
overall cancer. Each is based on at least as many RRs as are
available for oesophageal, pancreatic and lung cancer, and
none shows a significant excess risk in ST users.
Objectives
The objective of this article is to provide a detailed com-
parison of the two reviews [1,2] in order to clarify why
these major differences in risk estimates have occurred.
Attention is restricted to the four cancers considered by
Boffetta et al. [1]
Differences between the estimates from the two reviews
Table 2 (oropharyngeal cancer [3-21]), Table 3 (oesopha-
geal cancer [4,18,22-25]), Table 4 (pancreatic cancer
[4,5,26-30]) and Table 5 (lung cancer [3-5,27,31]) sum-
marize the estimates used in the two reviews [1,2], with
comments on similarities and differences. Based on this
comparison, the details of the methodology given in our
review [2], and the rather brief description of their proce-
dures presented by Boffetta et al. [1], a number of general
observations can be made.
Sources of difference between the two reviews
Derivation of estimates
Whereas Boffetta et al. [1] limited themselves to using RR
estimates given in the source publication, we [2] calcu-
lated an estimate using available methodology [32-35]
where the required RR was not provided but could be
derived from data given in the publication,. We felt this
necessary so as to avoid omitting relevant studies com-
pletely or, when a study provided non-independent
results from subsets of the data, presenting results only for
one of the subsets.
Table 1: Comparison of our smoking-adjusted random-effects 
meta-analysis estimates with those of Boffetta et al.
Boffetta et al. [1] Lee and Hamling [2]
Cancer Na RR (95% CI)b Na RR (95% CI)b
Oropharyngeal 13 1.8 (1.1–2.9) 19 1.36 (1.04–1.77)
- published since 1990 Not given 14 1.00 (0.83–1.20)
Oesophageal 5 1.6 (1.1–2.3) 7 1.13 (0.95–1.36)
Pancreatic 6 1.6 (1.1–2.2) 7 1.07 (0.71–1.60)
Lung 5 1.2 (0.7–1.9) 6 0.99 (0.71–1.37)
Stomach Not given 8 1.03 (0.88–1.20)
Bladder Not given 10 0.95 (0.71–1.29)
Overall cancer Not given 7 0.98 (0.84–1.15)
a Number of individual estimates considered in meta-analysis.
b Smoking-adjusted estimates for any ST use.BMC Cancer 2009, 9:256 http://www.biomedcentral.com/1471-2407/9/256
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Table 2: Comparison of individual and overall (random-effects) estimates for the two reviews – oropharyngeal cancer
ST usea
Ref Type Exposure Inclusion of smokersb Reviewc Sex Relative risk (95% CI) Comments
[3] ST Current NS L&H M 2.02 (0.53–7.74)
(CPS-I) ST Current NS B M 2.0 (0.5–7.7) Estimates agreed
[3] ST Current NS L&H M 0.90 (0.12–6.71)
(CPS-II) ST Current NS B M 0.9 (0.1–6.7) Estimates agreed
[4] Snuff Ever SNS L&H M 1.10 (0.50–2.41)
Snuff Ever SNS B M 1.1 (0.5–2.4) Estimates agreed
[5] Snuff Ever SNS L&H M 0.7 (0.5–0.9)
Snuff Ever NS B M 0.8 (0.4–1.7) NS not SNS
[6] Snuff Ever SNS L&H M 3.1 (1.5–6.6) Too recent to be included by B
[7] Chew Ever SNS L&H M+F 2.05 (1.48–2.83)e Not included by B
[8] Chew Ever SNS L&H M 2.00 (1.16–3.47)e Not included by B
[9] ST Ever SNS L&H M 3.63 (1.02–12.95)e Not included by B
[10] Snuff Ever SNS L&H F 2.67 (1.83–3.90)e
Snuff Ever NSf B F 4.2 (2.6–6.7) Whites
Snuff Ever NSf B F 1.5 (0.5–4.8) Blacks
[11] ST Ever SNS B M 2.3 (0.2–12.9) Tongue cancer
ST Ever SNS B M 11.2 (4.1–30.7) Mouth cancer
Not included by L&H as no valid smoking adjustmentg
[12] ST Ever NS L&H F 6.2 (1.9–19.8)
ST Ever NS B F 6.2 (1.9–19.8) Estimates agree
[13] Snuff Ever NS L&H M+F 0.67 (0.08–5.75)e Not included by B
[14] ST Ever SNS L&H M+F 1.04 (0.41–2.68)e Not included by B
[15] ST Ever SNS L&H M 0.96 (0.70–1.33)e
Chew Ever SNS B M 1.0 (0.7–1.4) Chew not ST
[16] Chew Ever SNS L&H M 1.11 (0.81–1.53)e
Chew Ever NS B M 2.3 (0.7–7.3) NS not SNS
[17]h ST Ever SNS L&H M+F 1.43 (0.64–3.21)e Not included by B
[18] Snuff Ever SNS L&H M 0.98 (0.63–1.50)e
Snuff Ever SNS B M 1.4 (0.8–2.4) Oral cancer excluding pharynx
[19] Snuff Ever SNS L&H M+F 0.8 (0.5–1.3) Estimate for NS also available
Snuff Ever SNS B M+F 0.8 (0.5–1.3) Estimates agree
[20] ST Ever SNS L&H M 1.0 (0.4–2.3) Not included by B
[21] Snuff Ever SNS L&H M+F 0.7 (0.3–1.3) Not included by B
Total L&H 1.36 (1.04–1.77) 19 estimates
B 1.8 (1.1–2.9) 13 estimates
a ST = smokeless tobacco; Chew = chewing tobacco; ever exposure includes undefined use.
b NS = never smokers; SNS = smokers and nonsmokers combined (with adjustment for smoking).
c L&H = Lee and Hamling review [2]; B = Boffetta et al. review [1].
d To within rounding error, as B only expressed estimates to one decimal place.
e Estimated from data provided.
f B stated that the results were for never smokers, but L&H consider the result relates to non-current smoking. L&H's estimate is for current and non-current smokers 
combined.
g Valid smoking adjustment was impossible in this study as "for users of multiple tobacco products, only the primary product was recorded".
h The results were cited by Gross et al. [17] based on an unpublished report by Perry et al., "Attributable oral cancer risk due to smokeless tobacco use based on a case-
control study at Sinai Hospital in Detroit".BMC Cancer 2009, 9:256 http://www.biomedcentral.com/1471-2407/9/256
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Restriction to smoking-adjusted estimates
As noted earlier, Boffetta et al. [1] stated that they
"included only studies restricted to non-smokers and
studies that included smokers but were properly adjusted
for the possible confounding effect of tobacco smoking."
Though, as is so often the situation in smoking and health
literature, the term "non-smokers" was not defined, we
have assumed that "lifelong non-smokers" (i.e. never
smokers) was meant. What was meant by "properly
adjusted" was also undefined, and in practice it appears
that any smoking adjustment was accepted, as we could
find no case of a published smoking-adjusted RR that was
not included by Boffetta et al. This is not surprising since,
as noted in our review [2], only a small proportion of
studies took any account of daily consumption or dura-
tion of smoking. As a consequence, the smoking-adjusted
data in Tables 2, 3, 4, 5 taken from our review are also not
restricted on how the adjustment for smoking was carried
out.
Studies included
We included more studies in our review [2] than did Bof-
fetta et al [1] in theirs. Mainly these are studies [7-
9,13,14,17,23,27] where the estimate required calcula-
tion, but three studies [20,21,31] appear to have been
overlooked by Boffetta et al., and there is also a recent
study [6] published after September 2007, the cut-off date
for their literature search. There is only one study [11]
included by Boffetta et al., but not by us. This study did
not provide results for never smokers, and though it
claimed to have presented estimates adjusted for tobacco
use, this appears impossible as the authors stated that "for
users of multiple tobacco products, only the primary
product was recorded." A comparison of ST users with
non-users of tobacco will therefore be biased by smokers
being included only in the group using ST.
ST type
The majority of studies presented results only for one type
of ST, usually either snuff specifically (typical for Scandi-
navian studies) or for overall ST use. A few studies provide
separate RRs for snuff and chewing tobacco. The RRs we
used in our meta-analyses [2] were based on overall ST use
if possible, calculated if necessary from the separate
results. We note that there were two studies [15,30] where
results were available for snuff and chewing tobacco, and
where Boffetta et al. [1] included only the results for chew-
ing tobacco.
ST exposure
The great majority of the studies present only RRs for
either ever use or unspecified use (which both reviews
Table 3: Comparison of individual and overall (random-effects) estimates for the two reviews – oesophageal cancer
ST usea
Ref Type Exposure Inclusion of smokersb Reviewc Sex Relative risk (95% CI) Comments
[4] Snuff Ever SNS L&H M 1.40 (0.61–3.24)
Snuff Ever SNS B M 1.4 (0.6–3.2) Estimates agreed
[22] Snuff Ever SNS L&H M 1.00 (0.79–1.27)e Estimate for NS also available
Snuff Ever NS B M 3.5 (1.6–7.6) NS not SNS; squamous cell carcinoma not all 
oesophageal cancer
[23] Chew Ever NS L&H M 1.18 (0.28–4.90)e Not included by B
Chew Ever NS L&H F 2.69 (0.92–7.87)e Not included by B
[24] ST Ever NS L&H M 1.2 (0.1–13.3)
ST Ever NS B M 1.2 (0.1–13.3) Estimates agree
[18] Snuff Ever SNS L&H M 1.2 (0.7–2.2)
Snuff Ever SNS B M 1.2 (0.7–2.2) Estimates agree
[25] Snuff Ever SNS L&H M+F 1.31 (0.89–1.92)e
Snuff Ever SNS B M+F 1.4 (0.9–2.3) Squamous cell carcinoma not all oesophageal cancer
Total L&H 1.13 (0.95–1.36) 7 estimates
B 1.6 (1.1–2.3) 5 estimates
a ST = smokeless tobacco; ever exposure includes undefined use.
b NS = never smokers; SNS = smokers and nonsmokers combined (with adjustment for smoking).
c L&H = Lee and Hamling review [2]; B = Boffetta et al. review [1].
d To within rounding error, as B only expressed estimates to one decimal place.
e Estimated from data provided.BMC Cancer 2009, 9:256 http://www.biomedcentral.com/1471-2407/9/256
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[1,2] have considered as essentially equivalent to ever
use). Some studies present results for current and former
use, and our procedure was to include the result for cur-
rent use only if an estimate for ever use was not available
or could not be calculated. Since they did not calculate RR
estimates, Boffetta et al. [1] included current rather than
ever use estimates for lung cancer for CPS-II [3]. However,
otherwise the two sets of estimates agree as regards ST
exposure.
Selection of results according to smoking history
There are a number of studies where RRs are available
both for never smokers and for smokers and non-smokers
combined, with adjustment for smoking. In the meta-
analyses shown in Table 1 taken from our review [2], we
have always included the smoker/non-smoker combined
estimate from these studies, on the basis that they pro-
vided greater power, though our review also presents the
results of meta-analyses of RRs specifically for never
smokers. Boffetta et al. [1] appear not to have defined any
rule here. In three such studies [5,22,30] they include
results for never smokers, and in two studies [4,19] the
results for smokers and non-smokers combined, without
any supporting explanation.
Types of cancer
Where results are available by type of cancer, we have
always included estimates for the total cancer being con-
sidered, but this is not the case for Boffetta et al [1]. Thus
whereas, for Table 2, we [2] include RRs for overall
oropharyngeal cancer, if available, only considering can-
cers of particular regions of the oropharynx if these were
the only data presented, Boffetta et al. omitted relevant
results for pharynx cancer in one study [18] and presented
RRs separately for mouth and tongue cancer in another
[11], a study in which results were also available for a
number of other regions of the oropharynx. For oesopha-
geal cancer, there are two studies [22,25] where Boffetta et
al. included results only for squamous cell carcinoma,
omitting those for adenocarcinoma, despite the other
studies in their analysis only presenting results for overall
oesophageal cancer.
Table 4: Comparison of individual and overall (random-effects) estimates for the two reviews – pancreatic cancer
ST usea
Ref Type Exposure Inclusion of smokersb Reviewc Sex Relative risk (95% CI) Comments
[26] ST Ever SNS L&H M 1.7 (0.9–3.1)
ST Ever SNS B M 1.7 (0.9–3.1) Estimates agree
[4] Snuff Ever SNS L&H M 1.67 (1.12–2.50) Estimates for NS also available
Snuff Ever SNS B M 1.7 (1.1–2.5) Estimates agreed
[5] Snuff Ever SNS L&H M 0.9 (0.7–1.2)
Snuff Ever NS B M 2.0 (1.2–3.3) NS not SNS
[27] ST Ever SNS L&H M 0.29 (0.09–0.92)e Not included by B
[28] Chew Ever NS L&H M 2.82 (0.85–9.39) Personal communication from Dr Muscat
Chew Ever NSf B M 3.6 (1.0–12.8) Estimate actually for non-current smokers
[29] ST Ever NSg L&H M+F 1.1 (0.4–3.1)
ST Ever NS B M+F 1.4 (0.5–3.6) Estimate biased as pipe and cigar smokers included in 
numerator only
[30] ST Ever SNS L&H M+F 0.65 (0.43–0.97)e Estimate for NS also available
Chew Ever NS B M+F 0.6 (0.3–1.4) Chew not ST; NS not SNS
Total L&H 1.07 (0.71–1.60) 7 estimates
B 1.6 (1.1–2.2) 6 estimates
a ST = smokeless tobacco; ever exposure includes undefined use.
b NS = never smokers; SNS = smokers and nonsmokers combined (with adjustment for smoking).
c L&H = Lee and Hamling review [2]; B = Boffetta et al. review [1].
d To within rounding error, as B only expressed estimates to one decimal place.
e Estimated from data provided.
f See comment.
g Never cigarette smokers, with adjustment for other tobacco use.BMC Cancer 2009, 9:256 http://www.biomedcentral.com/1471-2407/9/256
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Unnecessary inclusion of a confounded result
In one study [29] Boffetta et al. [1] selected a RR for never
cigarette smokers in which ST users who may also have
smoked pipes or cigars were compared with user of no
tobacco at all. We [2] preferred an estimate using those
who had only used ST as the numerator, to avoid bias
from pipe and cigar smoking.
Meta-analysis
Although Boffetta et al. [1] did not define their method, it
appears that they used random-effects estimates as we [2]
did, since for three of the cancers we calculated the overall
estimate from their data under this assumption and
obtained the same answer they did. We could not check
this for lung cancer as they presented only four individual
study RRs, but gave an overall estimate based on five.
Effect of the differences
The fact that for some studies we calculated RRs from data
available, combining evidence from data subsets to make
fuller use of the data, and that we applied a consistent rule
for choosing between RRs for never smokers and RRs for
smokers and non-smokers combined has led to differ-
ences between the RRs we include in our meta-analyses
[2] and those used by Boffetta et al. [1]. Some of the dif-
ferences are minor, but it is apparent that where there are
substantial differences, they are always in one direction,
with our systematic and arguably more complete analysis
providing lower smoking-adjusted RRs than theirs.
Five particular cases deserve comment. For oesophageal
cancer, Zendehdel et al. [22] reported never smoking RRs
of 3.5 (95% CI 1.6–7.6) for squamous cell carcinoma, 0.2
(0.0–1.9) for adenocarcinoma, as well as smoking-
adjusted RRs of 1.0 (0.8–1.4) for squamous cell carci-
noma and 1.0 (0.6–1.5) for adenocarcinoma. Our smok-
ing-adjusted RR shown in Table 3 was derived by
combining the last two relative risks to give 1.00 (0.79–
1.27), whereas Boffetta et al. [1] used only the first, high,
estimate of 3.5 (1.6–7.6).
For pancreatic cancer, the RR selected by Boffetta et al. [1]
for the study by Luo et al. [5] was that for never smokers
(2.0, 1.2–3.3) and not the smoking-adjusted estimate
(0.9, 0.7–1.2) we [2] used. In contrast in the Norway
cohorts study [4] both reviews used the smoking-adjusted
RR of 1.67 (1.12–1.50), Boffetta et al. here not selecting
the lower never smoker estimate of 0.85 (0.24–3.07).
Also, as noted above for the study by Alguacil and Silver-
man [29], Boffetta et al. selected a higher, but biased, RR
of 1.4 (0.5–3.6) when we used an estimate of 1.1 (0.4–
3.1).
Table 5: Comparison of individual and overall (random-effects) estimates for the two reviews – lung cancer
ST usea
Ref Type Exposure Inclusion of smokersb Reviewc Sex Relative risk (95% CI) Comments
[31] ST Ever NS L&H F 6.80 (1.60–28.5) Not included by B
[3] ST Current NS L&H M 1.08 (0.64–1.83)
(CPS-I) ST Current NS B M 1.1 (0.6–1.8) Estimates agreed
[3] ST Ever NS L&H M 1.77 (1.14–2.74)e
(CPS-II) ST Current NS B M 2.0 (1.2–3.2) Current not ever exposure
[4] Snuff Ever SNS L&H M 0.80 (0.61–1.05) Estimate for NS also available
Snuff Ever SNS B M 0.8 (0.6–1.1) Estimates agreed
[5] Snuff Ever SNS L&H M 0.7 (0.6–0.7)
Snuff Ever NS B M 0.8 (0.5–1.3) NS not SNS
[27] ST Ever SNS L&H M 0.69 (0.47–1.00)e Not included by B
Total L&H 0.99 (0.71–1.37) 6 estimates
B 1.2 (0.7–1.9) 5 estimatesf
a ST = smokeless tobacco; ever exposure includes undefined use.
b NS = never smokers; SNS = smokers and nonsmokers combined (with adjustment for smoking).
c L&H = Lee and Hamling review [2]; B = Boffetta et al. review [1].
d To within rounding error, as B only expressed estimates to one decimal place.
e Estimated from data provided.
f B only presented four estimates, but a combined result stated to be based on five. The random-effects estimate for the four estimates provided is 
1.1 (0.7–1.6)BMC Cancer 2009, 9:256 http://www.biomedcentral.com/1471-2407/9/256
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For oropharyngeal cancer, in the study of Kabat et al. [16],
Boffetta et al. chose a never smoker estimate of 2.3 (0.70–
7.3) rather than the smoking-adjusted RR of 1.1 (0.81–
1.53) we [2] used, while in the study of Lewin et al. [18]
they chose an estimate of 1.4 (0.8–2.4) for oral cancer
overlooking one of 0.7 (0.4–1.3) for pharyngeal cancer,
rather than the combined oropharyngeal RR we used of
0.98 (0.63–1.50).
Exclusion of relevant studies, and in one case [11] inclu-
sion of RRs that seem not to be smoking-adjusted, have
also contributed to the difference. This is considered fur-
ther below, where we comment on the four cancers in
turn.
Oropharyngeal cancer (Table 2)
Based on the 13 individual estimates provided by Boffetta
et al. [1], we calculate the random-effects meta-analysis
estimate as 1.82 (1.14–2.90), agreeing, to one decimal
place, with their figure of 1.8 (1.1–2.9). This is markedly
higher than the combined estimate of 1.36 (1.04–1.77)
based on the RRs we included. Eliminating the RRs from
the Stockwell and Lyman study [11], which appear not to
be smoking adjusted, would reduce Boffetta et al.'s esti-
mate to 1.54 (0.99–2.38) and further, for reasons noted
earlier, replacing their RR estimates from the studies by
Kabat et al. [16] and Lewin et al. [18] by ours would
reduce the combined estimate further, to 1.36 (0.94–
1.98), making it similar to ours [2]. Adding in the extra
studies we included [6-9,13,14,17,20,21] has little effect
on the overall estimate.
The conclusions of Boffetta et al. [1] regarding the role of
ST, as used in Western countries, on the risk of oropharyn-
geal cancer fail to take account of the additional evidence
in our review [2] and elsewhere [36] that any excess risk
essentially vanishes when attention is limited to studies
that have adjusted for alcohol as well as smoking. While
there may have been some effect in the past of ST as used
in the USA, Boffetta et al. refrain from commenting on the
fact that RR estimates have declined markedly over time.
This decline is illustrated clearly in Figure 1 where the con-
sistent (heterogeneity p = 0.34) evidence of an increase
seen in case-control studies published before 1990 con-
trasts sharply with the consistent (heterogeneity p = 0.93)
total lack of evidence of an increase in case-control studies
published more recently. The prospective studies, each of
which involves a long-term follow-up period starting
many years ago (1959–1972, 1982–2000, 1966–2001,
1978–2004, 1973–2002 for the five studies in Figure 1 in
order), give results that are heterogeneous (p = 0.004) and
suggest an intermediate increase. (It should be noted that
for other cancers the data are too limited to allow useful
comparison between studies published before and after
1990)
Oesophageal cancer (Table 3)
Here the meta-analysis estimate we calculate based on the
five RRs given by Boffetta et al. [1] is 1.57 (1.09–2.28),
matching the estimate they give, of 1.6 (1.1–2.3). The dif-
ference between this estimate and ours (1.13, 0.95–1.36)
is virtually wholly due to the RRs selected for the study by
Zendehdel et al. [22], as replacing their estimate by ours
for this study reduces their combined estimate to 1.10
(0.91–1.34), similar to our estimate of 1.13 (0.95–1.36).
We consider that there is no convincing evidence that ST
increases the risk of oesophageal cancer. The results from
the Zendehdel et al. study [22] suggesting an increase spe-
cifically for never smokers as regards squamous cell carci-
noma clearly need confirmation by other studies before
any reliable conclusion can be drawn.
Pancreatic cancer (Table 4)
Based on the data of Boffetta et al. [1], our combined esti-
mate is 1.57 (1.09–2.25), agreeing with their 1.6 (1.1–
2.2), but markedly higher than the estimate based on our
data, of 1.07 (0.71–1.60). Amending, for reasons dis-
cussed above, the estimates for the studies by Luo et al. [5]
and by Alguacil and Silverman [29] to the ones we used
would reduce their overall figure to a non-significant 1.25
(0.83–1.88).
Our estimate of 1.07 (0.71–1.60) is somewhat lower than
this due to inclusion of the low estimate we calculated
from the Williams and Horm study [27]. As discussed
elsewhere [37], where there is a fuller discussion of the
evidence on this cancer, some objections can be made
about this study. However the conclusion from our review
[2], that any effect of ST on pancreatic cancer has not been
clearly demonstrated, seems justified by the data whether
or not results from this study are included.
Lung cancer (Table 5)
We cannot evaluate the lung cancer meta-analyses of Bof-
fetta et al. [1] due to their only providing four of the five
individual RRs they used. However, their RRs are quite
similar to ours for the four studies where comparison is
possible. Our analysis [2] also includes a high RR from
one study [31] and a low RR from another [27] and we
agree that an association has not been demonstrated.
Discussion and conclusion
We believe that our review [2] offers a more robust meta-
analysis of the data than previously conducted by Boffetta
et al. [1] for a number of reasons. One reason is the use of
derived as well as published estimates, which adds consid-
erably to the data available for analysis, an approach
which might be improved still further by obtaining results
for those studies which merely reported their findings
non-quantitatively, e.g. as "no significant association."BMC Cancer 2009, 9:256 http://www.biomedcentral.com/1471-2407/9/256
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Other reasons include ensuring that all the RRs used were
in fact adjusted for smoking, and the use of a pre-defined
systematic procedure to decide which estimates to include
in the meta-analysis. The differences in procedures had
the largest effect for pancreatic cancer and oesophageal
cancer. For pancreatic cancer, significant increases for
never smokers in one study [5] and for smokers and non-
smokers combined in another study [4] were selected by
Boffetta et al., ignoring estimates showing a lack of any
increase at all for smokers and non-smokers combined in
the first study [5] and for never smokers in the second [4].
For oesophageal cancer, given results for one study [22]
which showed a significantly increased RR among never
smokers for squamous cell carcinoma but no increase at
all among never smokers for adenocarcinoma, or among
smokers and non-smokers combined for either cell type,
Boffetta et al. elected to include only the significant RR,
despite the inherent bias from such a procedure. For
oropharyngeal cancer, although Boffetta et al. recognized
the lack of evidence of a relationship for studies con-
ducted in Scandinavia, their claim of an effect for ST as
used in the USA fails to recognize that this is no longer
seen in more recent studies.
As a result of using a more systematic and more inclusive
process we believe that our analysis [2] provides a more
accurate estimate of any relationship of ST with risk of
cancer. Previous claims of significant increases for
oropharyngeal, oesophageal and pancreatic cancer with
risk increases of 60% to 80% for each cancer [1], appear
unjustified when more appropriate meta-analyses are
conducted. For the oesophagus and pancreas the esti-
mated risk increases based on smoking-adjusted data
should be more like 10% and not statistically significant,
while for oropharyngeal cancer we estimate the increase
to be a marginally significant 36% when all the data are
considered, and to be zero when attention is restricted to
studies published since 1990.
Variation in RR of ST-associated oropharyngeal cancer by study type and period of publication Figure 1
Variation in RR of ST-associated oropharyngeal cancer by study type and period of publication. For each of 19 
studies, separated by study type and, for case-control studies, by period of publication, the individual study RR and 95% CI esti-
mates, taken from the Lee and Hamling review [2] (see also Table 2), are shown numerically and also graphically on a logarith-
mic scale. In the graphical representation, the RR is indicated by a solid square, with the area of the square proportional to the 
weight (inverse-variance) of the estimate. Also shown are the combined estimates, derived by random-effects meta-analysis, 
for the three subgroups and overall. Here the sizes of the four squares corresponding to the RRs are also proportional to the 
weight of the estimate, though the constant of proportionality differs from that for the individual RRs.
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Boffetta et al. [1] also claimed that the cancer risk of ST
users is only "probably" lower than that of smokers. Given
that, for the four cancers they consider, the RRs they esti-
mate are substantially lower than seen for smoking (par-
ticularly for lung cancer where their estimate of a 20%
increase for ST compares with an estimated increase of
about 2000% for current smokers and 1000% for former
smokers), it is unclear why they did not accept that the
risk for ST users is definitely much lower than for cigarette
smokers. This conclusion is even more evident using our
more appropriate risk estimates for ST, and in our review
[2] we estimate that attributable deaths from smoking-
related cancers would be almost 100 times lower, if smok-
ers instead had the risk of ST users.
While, as discussed in our review [2], the evidence we
have considered has many weaknesses and, as Boffetta et
al. state in their review [1], the health effects of ST prod-
ucts need to be better characterized, we feel it is important
that appropriate inferences are drawn from the data that
are available so as to put the likely cancer risks from use of
ST into a proper perspective versus the risks of smoking
cigarettes. This is important given that some public health
authorities see a potential role for ST in tobacco harm
reduction [38-40]. We also feel that this investigation
underlines the advantage of a pre-defined systematic pro-
cedure for conducting meta-analyses. It is essential that all
relevant data should be used, and that clear rules should
be present for choosing between alternative estimates
from the same study.
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